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SUMMARY · The development of atrial pacing for prevention of drug refractory atrial fibrillation
was a logical step in the management of this arrhythmia. The electrophysiologic rationale for the
efficacy of atrial pacing is based on the reduction of global and local atrial activation times during
pacing, which results in reduced dispersion of atrial refractoriness and decreased interatrial conduc-
tion delay. However, the atrial pacing strategy should be considered in different populations with
atrial fibrillation. To date, there is increasing evidence that single site atrial pacing is beneficial for
atrial fibrillation prevention in patients with sick sinus syndrome. Both dual-site right atrial and
interatrial septal pacing have an incremental benefit as compared with single-site right atrial pacing,
and can be used in selected patients with resistant symptomatic atrial fibrillation, especially if they
have prolonged interatrial conduction. The efficacy of biatrial pacing is still unproven, and techni-
cally is associated with frequent coronary sinus lead dislodgment. Further studies with multi-site atrial
pacing and new algorithms for atrial fibrillation prevention are needed, possibly in combination with
antiarrhythmic drug therapy or ablation, which should expand the use of atrial stimulation in the
treatment of symptomatic atrial fibrillation.
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Introduction
The occurrence of atrial fibrillation frequently cannot
be prevented by the administration of antiarrhythmic
drugs, or effective drugs may not be tolerated or may cause
side effects. In view of these consequences and risks of
atrial fibrillation, the development and application of atrial
pacing have been a logical step in the treatment of this
arrhythmia. The mechanism of atrial pacing in the pre-
vention of atrial fibrillation is now better understood.
Atrial pacing has an effect on the substrate and triggers
responsible for the emergence of atrial fibrillation1,2. It
also has effects on the mechanic atrial function and neu-
rohumoral system. By acting on the substrate, atrial pac-
ing reduces dispersion of atrial refractoriness and intera-
trial conduction delay. Both of these effects result in a
reduced window for atrial fibrillation. In addition, there
is evidence that an overdrive atrial pacing may suppress
premature atrial beats3. In this article, the essential ele-
ments of the rationale electrophysiologic basis, and clinical
experience reported to date with this therapeutic approach
in the prevention of atrial fibrillation will be reviewed.
Single-Site Atrial Pacing
During the last ten years, several retrospective stud-
ies have found that atrial pacing in patients with sick si-
nus syndrome is associated with a significantly lower in-
cidence of atrial fibrillation and mortality compared with
ventricular pacing4-7. The main criticism on these stud-
ies refers to bias in mode selection and inability to account
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for the effect of associated comorbidity. The Danish study
was the first one that prospectively examined the effects
of atrial versus ventricular pacing in patients with sick si-
nus syndrome (Table 1)8. At the time of randomization,
all patients had sinus rhythm, but about 45% of them had
episodes of atrial fibrillation periodically. Over a mean
follow-up period of 5.5 years, the cumulative incidence of
atrial fibrillation events and chronic atrial fibrillation was
significantly lower and survival was significantly higher in
the atrial than in the ventricular pacing group. In an ini-
tial report, these investigators did not observe any signifi-
cant mortality difference in this study when patients were
followed up for only 3.3 years9.This observation raises the
possibility of a delayed biological effect of atrial pacing
therapy.





Number of patients 110 115
- with AF episodes
at randomization 43 51 <0.51
- with AF episodes
at control 26 40 <0.012
- with chronic AF 9 22 <0.004
Cardiovascular death 19 39 <0.0065
AF=atrial fibrillation
Recently, the Canadian Trial of Physiologic Pacing
(CTOPP) has shown that the annual rate of atrial fibril-
lation is significantly lower among the physiologic pacing
group patients (dual chamber or atrial pacing system) than
among those of the ventricular pacing group (5.3% versus
6.6%, p<0.05), with a relative risk reduction of 18%10.The
beneficial effect of physiologic pacing on the rate of atrial
fibrillation was not apparent until two years following im-
plantation. In the CTOPP trial, the survival curves appear
to be diverging after 4 years, although the numbers followed
for this duration are small. Because of this, the CTOPP in-
vestigators have decided to continue to follow up the
CTOPP patients for an additional 3 years to determine
whether a delayed benefit of physiologic pacing over ven-
tricular pacing will occur. In the CTOPP study, only 5.5%
of patients randomized to physiologic pacing received an
atrial pacing system, while others received atrioventricular
(AV) sequentional pacing. Subgroup analysis in CTOPP
suggests that patients younger than 75 without significant
structural heart disease are more likely to benefit from
physiologic pacing for prevention of atrial fibrillation11.
This is consistent with Danish study because the patients
with intact AV conduction tend to be younger and
healthier than the general pacemaker population. The
exact mechanism that links atrial pacing with a clinical
benefit is not quite clear. Ventricular pacing may predis-
pose, or atrial pacing may prevent or delay the natural
evolution of sinus node disease to chronic atrial fibrilla-
tion. The explanation might be related to atrial overdrive
pacing eliminating sinus bradycardia with concomitant
homogenization of atrial refractory period, or to preserved
AV synchrony, or both. However, it is not known whether
atrial pacing did really reduce atrial fibrillation, or it was
only exhibiting less atrial fibrillation than ventricular pac-
ing because neither of these prospective studies had a
control group of patients without pacing.
The use of rate-adaptive atrial pacing in the prevention
of atrial fibrillation in the absence of symptomatic bradycar-
dia was recently evaluated in the study of Gillis et al.12.
Medtronic Thera dual chamber rate responsive pacemaker
was implanted in 97 patients with drug refractory parox-
ysmal atrial fibrillation 3 months before planned AV node
ablation. Patients were randomized to no pacing (n=48) or
atrial rate-adaptive pacing (n=49) group. Over a 10-week
period, the paroxysmal atrial fibrillation burden was lower
in the no pacing group than in the atrial pacing group, while
the time to first episode of sustained paroxysmal atrial fibril-
lation was similar in both groups. These results show that
atrial rate-adaptive pacing does not prevent paroxysmal
atrial fibrillation over short term in patients with drug-
resistant paroxysmal atrial fibrillation without symptomatic
bradycardia. For better evaluation of atrial pacing in the
population of such patients, studies with longer follow-up
are needed, because a delayed beneficial effect of atrial pac-
ing was observed in Danish and CTOPP studies8,10.
Dual-Site Atrial Pacing
Atrial and/or interatrial conduction blocks result in
delayed activation of the left atrium, and they are thought
to be associated with inhomogeneous atrial conduction
and dispersion of atrial refractoriness, favoring the initia-
tion of atrium’s fibrillation. It is reasonable to presume
that permanent atrial resynchronization should result in
preventing arrhythmia recurrence. Dual-site atrial pacing
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has been performed by simultaneous stimulation of the
high right atrium and either coronary sinus ostium (dual-
site right atrial pacing), or distal coronary sinus (biatrial
pacing)13,14. Both pacing modalities significantly shorten
P-wave duration due to two simultaneously originating
wavefronts, with fusion occurring in the region of crista
terminalis and coronary sinus ostial area.
In a prospective, crossover study, Default et al. exam-
ined the benefit of dual-site right atrial pacing in 30 pa-
tients who had atrial fibrillation refractory to drug
therapy13. The two pacing leads were fixed in the right
atrium, one at the high right atrium and the other just
outside the coronary sinus, while ventricular lead was
positioned at the right ventricular apex. The primary in-
dication for cardiac pacing was sick sinus syndrome in
eight, conduction system disease in six, drug-induced
bradycardia in eleven, and neurocardiogenic syncope with
bradycardic mechanism in five patients. During 9 months,
the freedom from any atrial fibrillation recurrence was
significantly higher during dual-site than during single-
site right atrial pacing (89% versus 62%, p<0.02). High
right atrial pacing and coronary sinus ostial pacing did not
differ in efficacy. Over the 3-year follow-up, the three
groups of patients could be substratified in this study (Fig.
1). In about 10% of patients, dual-site right atrial pacing
could not achieve control over the follow-up. About 50%
of patients were free from atrial fibrillation recurrence, and
40% of patients had infrequent relapses of atrial fibrilla-
tion requiring adjunctive drug therapy. The benefit of
dual-site right atrial pacing was seen in patients with and
without manifest bradyarrhythmias at the time of atrial
fibrillation emergence. This would suggest that this ben-
eficial effect is rather due to direct action on atrial arrhyth-
mia by changing slow conduction in regional areas, or by
reduction in dispersion of refractoriness, than mediated by
bradycardia prevention. The presence of cardiac disease
was noted in 73% of patients, proving that this technique
can be successfully used in atrial fibrillation population
with and without structural heart disease.
In a recent study, Leclercq et al. compared the efficacy of
dual-site and single-site right atrial pacing in 83 patients
who received a dual chamber pacemaker for primary sinus
node dysfunction or bradycardia with documented atrial fi-
brillation14. Inclusion criteria for dual-site pacing was a P-
wave >120 ms and at least two episodes of documented



















Fig. 1. Long-term results of dual-site right atrial pacing in the prevention of atrial fibrillation. See text for explanation. CAF=chronic
atrial fibrillation, pts=patients (modified from ref. 13).
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implantation. Dual-site right atrial pacing was performed
in 30 patients, and single-site in 21 patients with P-wave
>120 ms and 32 with P-wave <120 ms. During a mean
follow-up of 18 months, dual-site right atrial pacing was
more effective than single-site atrial pacing in reducing
paroxysmal and permanent atrial fibrillation only in pa-
tients with P-wave duration >120 ms. Comparison between
dual-site patients and the group of single-site patients with
P-wave duration <120 ms did not yield any significant dif-
ferences in the incidence of paroxysmal and permanent atrial
fibrillation. Thus, no benefit could be expected from dual-site
atrial pacing in patients with normal P-wave duration.
Biatrial pacing was first introduced by Daubert et al. for
the treatment of severe intra- and/or interatrial conduction
delay in patients with sick sinus syndrome15. A screw-in
fixation lead was used in the right atrium and passive fixa-
tion lead in the coronary sinus. In a recent study carried out
by this group, biatrial pacing was evaluated in a subpopu-
lation of 86 patients with drug refractory atrial fibrillation
and interatrial conduction delay of more than 100 ms16.
During biatrial pacing, the mean duration of P-wave was
shortened from 87 to 105 ms. After a mean follow-up of 33
months, 64% of patients remained in sinus rhythm and 33%
were free from atrial fibrillation recurrence. The only pre-
dictive factor of positive response to biatrial pacing was P-
wave duration of more than 160 ms at baseline evaluation.
It is quite obvious that in this subpopulation of patients
biatrial pacing reduces total atrial activation time and
modifies or eliminates regional areas of slow conduction.
Coronary sinus lead dislodgment, seen in 20% of patients,
was the major technical problem. The main limitation of this
study was the absence of randomized or crossover compari-
son with single-site atrial pacing. Therefore, it is not clear
whether the beneficial effect was obtained by biatrial or high
atrial pacing.
In the recent randomized, crossover SYNBIAPACE
study, Mabo et al. examined the efficacy of biatrial pac-
ing versus single-site high atrial dual chamber pacing in
the prevention of atrial arrhythmias in 42 patients with
interatrial conduction block >100 ms17. The primary end-
point was to compare the time to first atrial arrhythmia
recurrence as monitored by Holter functions of the pace-
maker among three pacing modes: biatrial pacing at a
basic rate of 70 beats per minute, single-site high right
atrial dual chamber pacing at 70 beats per minute, and the
same pacing mode at 40 beats per minute. Although a trend
towards reduction in the incidence of atrial arrhythmias was
observed during biatrial pacing, the study found no real
benefit from this pacing mode in these selected patients.
Interatrial Septal Pacing
The rationale for interatrial septal pacing is to achieve
synchronous depolarization of both atria without concern
for interatrial conduction. It is suggested that such a pac-
ing system allows for an optimal timing of the left-sided
AV delay18. The validity of this pacing system was exam-
ined by Padeletti et al. in 25 patients with paroxysmal atrial
fibrillation (about 6 episodes per month) and sinus brady-
cardia19. In order to achieve interatrial septal stimulation,
a steroid eluting screw-in lead was positioned just above
the sinus coronary ostium and connected to dual cham-
ber pacemaker (Medtronic Thera or Kappa DR). With
septal stimulation, the mean P-wave duration decreased
from 118 to 86 ms. During 10-month follow-up, two
patients complained of only one episode of paroxysmal
atrial fibrillation, and four patients had short-lasting (<6
min) symptomatic attacks of this arrhythmia. Nineteen
(76%) patients were completely free from paroxysmal
atrial fibrillation recurrence.
Recently, the same group prospectively compared the
efficacy between interatrial septal pacing and right atrial
appendage pacing in 39 patients with symptomatic par-
oxysmal atrial fibrillation and sinus node disease20. In all
patients, dual chamber pacemaker (Medtronic Thera DR)
was implanted. Patients were randomized as for atrial
pacing site, 18 to interatrial septal pacing and 12 to right
atrial pacing. After a period of 6 months, interatrial sep-
tal pacing was significantly more efficacious in maintain-
ing sinus rhythm and reduction of symptomatic paroxys-
mal atrial fibrillation recurrence than right atrial pacing.
The beneficial effect of interatrial septal pacing is mani-
fested by simultaneous activation of both atria, avoiding
interatrial conduction delay, and by pre-excitation of the
triangle of Koch that is known to be the zone of nonuni-
form anisotropic conduction.
New Algorithms for Prevention of
Atrial Fibrillation
There are several algorithms for prevention of atrial
fibrillation, incorporated in new pacemaker generations,
that are now in the phase of clinical investigation. The
Premature Atrial Complex suppression algorithm is utilized
in the AF-therapy European study21. If premature atrial
beat is sensed, the pacing rate increases by 15 beats per
minute over the mean basic cycles. This rate is maintained
for 600 beats, thereafter beginning slow slackening of 1
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beat per minute every 16 cycles. To avoid too high a rate
of atrial pacing, this algorithm is applied only once after
the activation.
The Pace Conditioning algorithm intends to overdrive
the atrium constantly at a rate just above the spontane-
ous sinus rate21. It utilizes the same parameters as the
Premature Atrial Complex algorithm without a plateau of
600 beats, and the trigger is the sense of intrinsic sinus
activity.
The Consistent Atrial Pacing and Overdrive Atrial
Pacing algorithms are aimed at the same result3,22. After
every sensed atrial event outside the postventricular refrac-
tory period, the atrial escape interval is shortened by a
programmable value until the programmed upper rate
value. After the programmable number of paced atrial
events, the atrial escape interval is lengthened by a pro-
grammable value until the programmed lower rate value
is reached.
The Dynamic Atrial Overdrive algorithm is designed
so that the atrial pacing rate is always just above the patient’s
intrinsic atrial rate. It accomplishes this by continually
monitoring the atrial rate and promptly increasing the
stimulation rate when the intrinsic rhythm emerges. Be-
cause the algorithm routinely searches for intrinsic atrial
activity and adjusts the stimulation rate accordingly, it
avoids needless rapid stimulation and preserves normal cir-
cadian rate variation and chronotropic response.
The aim of the Atrial Rate Stabilization algorithm is
to prevent long pauses after intrinsic premature atrial
beats, which are the potential trigger mechanism of atrial
tachyarrhythmia episodes. This algorithm measures each
atrial interval delivering the next pacing escape interval
at the same interval plus a programmable percentage. In
case of an early premature atrial beat, the short previous
interval is measured and the subsequent cycle is only a
little longer but still much shorter than the base or sen-
sor defined interval (Fig. 2).
The Post Mode Switch Overdrive Pacing algorithm
is designed to suppress early recurrence of atrial fibrilla-
tion. Upon termination of an atrial tachyarrhythmia via
dual chamber mode switch pacing and confirmation of
sinus rhythm, this algorithm delivers dual chamber over-
drive atrial pacing for a programmed period of time. Once
the overdrive period has elapsed, the pacing returns to the
programmed dual chamber mode.
The Atrial Preference algorithm maximizes atrial pac-
ing percentage to promote consistent activation rate. Upon
sensing sinus beats outside the refractory period, this algo-
rithm dynamically increases atrial pacing rate to be slightly
faster than sinus rate when atrial tachyarrhythmia is not
present. After several paced beats, the pacing interval is
gradually increased by 20 ms until sensing an intrinsic
rhythm, which triggers shortening of the pacing interval.
The last three algorithms presented have recently been
integrated into a dual chamber rate responsive pacemaker
system (Medtronic AT 500 model 72539) and were in-
vestigated prospectively in 31 patients with conventional
pacing indications and atrial tachyarrhythmias23. Results
of this study indicate that the three atrial preventive pac-
ing algorithms implemented in the new pacemaker sys-
tem reduced the number of atrial tachyarrhythmia epi-
sodes in patients with paroxysmal or persistent atrial fi-
brillation, but did not decrease the time during which
patients were in atrial tachyarrhythmia. No clinical vari-
Fig. 2. Atrial rate stabilization. Premature atrial beat (marked by arrow) occurs at 520 ms after stimulated P-wave of dual chamber pac-
ing. The device recognizes this and starts to stimulate atrium with the same interval (520 ms) plus programmable increament of 120 ms,
augmenting the stimulating interval in every next stimulated interval (700+120 ms, 800+120 ms) until an interval of basal atrial stimu-
lation is obtained (960 ms).
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able identified responders to atrial preventive pacing.
Conclusion
The atrial pacing strategy should be considered in dif-
ferent subpopulations of atrial fibrillation patients (Table
2).There is no doubt that patients with sick sinus syndrome
benefit from single-site atrial pacing. However, the benefit has
been observed only after a relatively long follow-up period in
younger patients without significant structural heart disease.
Clinical studies have demonstrated that both dual-site right
atrial pacing and interatrial septal pacing show an incremen-
tal benefit as compared with single-site atrial pacing in the
reduction of atrial fibrillation recurrencies. Thus, these tech-
niques can be effective and sufficient in patients with symp-
tomatic atrial fibrillation, who have a moderate atrial fibril-
lation burden and prolonged interatrial conduction. In a sub-
population who have a significant interatrial conduction
delay (>160 ms) and drug refractory atrial fibrillation with
or without bradycardia, biatrial pacing can be useful. Further
studies with multi-site atrial pacing are needed, possibly in
combination with antiarrhythmic drug therapy, or ablation,
which should expand this therapeutic approach and offer con-
siderable clinical benefit to selected patients with symptom-
atic atrial fibrillation. The new algorithms for prevention of
atrial fibrillation are promising, but their feasibility and ef-
ficacy should be confirmed in the ongoing trials.
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Saæetak
STIMULACIJA ATRIJA ZA PREVENCIJU ATRIJSKE FIBRILACIJE
D. PetraË i V. Leskovar
Razvoj stimulacije atrija za prevenciju atrijske fibrilacije refraktorne na lijekove predstavlja logiËan slijed u lijeËenju ove
aritmije. Elektrofiziolo¹ka svrsishodnost stimulacije atrija temelji se na smanjenju ukupnih i lokalnih vremena atrijske aktivacije
tijekom stimulacije, ¹to dovodi do smanjene disperzije atrijske refraktornosti i smanjenog ka¹njenja interatrijskog provoðenja.
Meðutim, primjenu stimulacije atrija treba razmotriti kod razliËitih populacija s atrijskom fibrilacijom. Danas ima dosta dokaza
da je jednostruka stimulacija atrija korisna u prevenciji atrijske fibrilacije u bolesnika sa sindromom bolesnog sinusnog Ëvora.
Dvostruka stimulacija desnog atrija ili septalna stimulacija atrija djelotvornije su od jednostruke i mogu se primijeniti u izabranih
bolesnika sa simptomatskom atrijskom fibrilacijom, osobito kod onih koji imaju produæeno interatrijsko provoðenje. Djelotvornost
biatrijske stimulacije jo¹ nije dokazana, a tehniËki je povezana s Ëestim dislokacijama elektrode u koronarnom sinusu. Potrebne su
buduÊe studije s vi¹estrukom stimulacijom atrija i/ili novim algoritmima za prevenciju atrijske fibrilacije, vjerojatno u kombinaciji
s lijekovima ili ablacijom, koje bi trebale pro¹iriti primjenu atrijske stimulacije u lijeËenju simptomatske atrijske fibrilacije.
KljuËne rijeËi: Atrijska fibrilacija, prevencija i kontrola; Umjetna srËana stimulacija, metode
